Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

The overall purpose of the study is to determine whether or not the inclusion of suramin to
standard treatment with docetaxel improves progression-free survival for patients with
advanced non-small cell lung cancer in the second and third line settings.

Secondary objectives include:

- To compare response rate of patients in both treatment arms

- To compare overall survival of patients in both treatment arms

- To compare toxicity in both treatment arms

- To determine whether the survival benefit from suramin is associated with reduced
M-phase entry in peripheral blood lymphocytes

Inclusion Criteria:

- Pathologically proven diagnosis of non-small cell lung cancer

- Documented disease progression after first-line chemotherapy for non-small cell lung
cancer

- Stable and treated CNS metastasis is allowed

- Radiation must be completed at least 2 weeks prior to starting protocol treatment

- Major surgery must be completed at least 4 weeks prior to starting protocol treatment

- ECOG performance status 0-2

- Sexually active patients must use adequate contraception

- Adequate bone marrow function

- Adequate renal function

- Adequate liver function

Exclusion Criteria:

- Severe hypersensitivity reaction to docetaxel

- Pre-existing grade 3 or 4 neuropathy

- Women who are pregnant or breastfeeding

- Uncontrolled intercurrent illness

- Receipt of 3 or more prior chemotherapy regimens